BioCardia, Inc. Warrant
BCDAW
BCDAW was delisted on the 2nd of August, 2024.
5 hedge funds and large institutions have $59.9K invested in BioCardia, Inc. Warrant in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
122% more capital invested
Capital invested by funds: $27K → $59.9K (+$32.9K)
0% more funds holding
Funds holding: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$12.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$21 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Osaic Holdings
Scottsdale,
Arizona
| $25K | – | – | – |
|
|
2
Citadel Advisors
Miami,
Florida
| $16.6K | +$12.9K | +20,545 | New |
|
|
G
3
GenTrust
Miami,
Florida
| $12.6K | – | – | – |
|
4
Bank of America
Charlotte,
North Carolina
| $4.74K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $913 | +$21 | +33 | +3% |
|
BCDAW Hedge Fund Activity: Q4 2022 in Review
5 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in BioCardia, Inc. Warrant (BCDAW) for Q4 2022, worth a combined $59.9K — up 122% from $27K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BCDAW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $12.9K.
- 5 institutional investors held BioCardia, Inc. Warrant (BCDAW) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $59.9K of BioCardia, Inc. Warrant stock for Q4 2022, up 122% quarter-over-quarter.
- 1 fund opened new BioCardia, Inc. Warrant positions in Q4 2022 and 0 closed out, a net change of +1 holder.
- The largest BioCardia, Inc. Warrant buyer in Q4 2022 was Citadel Advisors, an estimated $12.9K added.
Based on aggregated 13F filings for Q4 2022.